Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Vincerx Pharma Inc

VINC
Current price
0.36 USD -0.007 USD (-1.92%)
Last closed 0.37 USD
ISIN US92731L1061
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 11 271 529 USD
Yield for 12 month -61.09 %
1Y
3Y
5Y
10Y
15Y
VINC
21.11.2021 - 28.11.2021

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. The company is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with relapsed and refractory leukemia and lymphoid malignancies, as well as solid tumors and non-Hodgkin lymphoma; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat advanced or metastatic solid tumors. Its product candidates also include VIP943 in Phase 1 clinical trials for the treatment of relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia; and VIP924 in preclinical studies for the treatment of B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 and is based in Palo Alto, California. Address: 260 Sheridan Avenue, Palo Alto, CA, United States, 94306

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

6 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

-915 000 USD

Last Year

-939 000 USD

Current Quarter

-270 000 USD

Last Quarter

-264 000 USD

Key Figures VINC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -29 934 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -65.99 %
PEG Ratio
Return On Equity TTM -142.45 %
Wall Street Target Price 6 USD
Revenue TTM
Book Value 0.52 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -1.14 USD
Diluted Eps TTM -1.14 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics VINC

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History VINC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation VINC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -3.1328
Price Book MRQ 0.7296

Financials VINC

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators VINC

For 52 weeks

0.33 USD 9.37 USD
50 Day MA 0.6 USD
Shares Short Prior Month 289 250
200 Day MA 1.56 USD
Short Ratio 0.86
Shares Short 837 284
Short Percent 3.09 %